TB Archives – Page 38 of 49 – Treatment Action Group

2012 Symposium: Aspiring to Zero TB Deaths, New Infections, and Suffering

November 23, 2012
Chad Cipiti

On November 13 at the 2012 International Union Against TB and Lung Disease World Conference in Kuala Lumpur, Malaysia, Treatment Action Group (TAG), the Stop TB Partnership, the Sentinel Project on Pediatric Drug-Resistant Tuberculosis, Partners In Health (PIH), and the…

Treatment Action Group and the Stop TB Partnership Issue Update on 2011 Global TB R&D Investment Trends

November 14, 2012
Chad Cipiti

For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding.

2012 Report on TB Research Funding Trends

November 13, 2012
Chad Cipiti

Now in its seventh year, the Treatment Action Group (TAG) publishes the latest investment data and analysis on the state of global tuberculosis (TB) research and development (R&D) funding.

GeneXpert Rapid TB Test Price Reduced in Historic Agreement

October 3, 2012
Chad Cipiti

By Coco Jervis After months of political wrangling, in early July 2012, an agreement to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB) was reached between the manufacturer, Cepheid, and pooled purchasers UNITAID, the U.S. President's Emergency…

Getting to Zero—Join the Movement!

October 3, 2012
Chad Cipiti

By Colleen Daniels Tuberculosis (TB), a 40,000-year-old disease, still devastates communities although it has been preventable—and curable—for decades. In 2010, the World Health Organization (WHO) reported 8.8 million TB cases—1.4 million of them fatal—worldwide. TB is the leading cause of…

The Future of TB in the United States: Going, or Growing?

October 3, 2012
Chad Cipiti

By Erica Lessem This summer, Treatment Action Group (TAG) and its partners in fighting tuberculosis (TB) issued a call for zero TB deaths, zero new TB infections, and zero suffering from TB. Yet the U.S., long a leader in TB…

TAGline Fall 2012

October 3, 2012
Chad Cipiti

TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement

Treatment Action Group and European AIDS Treatment Group Applaud UNITAID Agreement to Reduce the Cost of GeneXpert Rapid TB Test

August 7, 2012
Chad Cipiti

Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG) welcome the announcement that a deal has been reached among PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to reduce the price of the GeneXpert MTB/RIF rapid test for tuberculosis (TB).

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery

July 21, 2012
Chad Cipiti

On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.

2012 Pipeline Report

July 20, 2012
Chad Cipiti

HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.